1 Report Overview 1.1 Study Scope 1.2 Market Analysis by Type 1.2.1 Global Bio Similars/Subsequent Entry Biologic Market Size Growth Rate by Type: 2016 VS 2021 VS 2027 1.2.2 Monoclonal Antibodies 1.2.3 Interferon 1.2.4 Erythropoietin 1.2.5 Insulin 1.2.6 Vaccines 1.2.7 Other 1.3 Market by Application 1.3.1 Global Bio Similars/Subsequent Entry Biologic Market Share by Application: 2016 VS 2021 VS 2027 1.3.2 Tumor 1.3.3 Diabetes 1.3.4 Cardiovascular 1.3.5 Hemophilia 1.3.6 Other 1.4 Study Objectives 1.5 Years Considered 2 Global Growth Trends 2.1 Global Bio Similars/Subsequent Entry Biologic Market Perspective (2016-2027) 2.2 Bio Similars/Subsequent Entry Biologic Growth Trends by Regions 2.2.1 Bio Similars/Subsequent Entry Biologic Market Size by Regions: 2016 VS 2021 VS 2027 2.2.2 Bio Similars/Subsequent Entry Biologic Historic Market Share by Regions (2016-2021) 2.2.3 Bio Similars/Subsequent Entry Biologic Forecasted Market Size by Regions (2022-2027) 2.3 Bio Similars/Subsequent Entry Biologic Industry Dynamic 2.3.1 Bio Similars/Subsequent Entry Biologic Market Trends 2.3.2 Bio Similars/Subsequent Entry Biologic Market Drivers 2.3.3 Bio Similars/Subsequent Entry Biologic Market Challenges 2.3.4 Bio Similars/Subsequent Entry Biologic Market Restraints 3 Competition Landscape by Key Players 3.1 Global Top Bio Similars/Subsequent Entry Biologic Players by Revenue 3.1.1 Global Top Bio Similars/Subsequent Entry Biologic Players by Revenue (2016-2021) 3.1.2 Global Bio Similars/Subsequent Entry Biologic Revenue Market Share by Players (2016-2021) 3.2 Global Bio Similars/Subsequent Entry Biologic Market Share by Company Type (Tier 1, Tier 2 and Tier 3) 3.3 Players Covered: Ranking by Bio Similars/Subsequent Entry Biologic Revenue 3.4 Global Bio Similars/Subsequent Entry Biologic Market Concentration Ratio 3.4.1 Global Bio Similars/Subsequent Entry Biologic Market Concentration Ratio (CR5 and HHI) 3.4.2 Global Top 10 and Top 5 Companies by Bio Similars/Subsequent Entry Biologic Revenue in 2020 3.5 Bio Similars/Subsequent Entry Biologic Key Players Head office and Area Served 3.6 Key Players Bio Similars/Subsequent Entry Biologic Product Solution and Service 3.7 Date of Enter into Bio Similars/Subsequent Entry Biologic Market 3.8 Mergers & Acquisitions, Expansion Plans 4 Bio Similars/Subsequent Entry Biologic Breakdown Data by Type 4.1 Global Bio Similars/Subsequent Entry Biologic Historic Market Size by Type (2016-2021) 4.2 Global Bio Similars/Subsequent Entry Biologic Forecasted Market Size by Type (2022-2027) 5 Bio Similars/Subsequent Entry Biologic Breakdown Data by Application 5.1 Global Bio Similars/Subsequent Entry Biologic Historic Market Size by Application (2016-2021) 5.2 Global Bio Similars/Subsequent Entry Biologic Forecasted Market Size by Application (2022-2027) 6 North America 6.1 North America Bio Similars/Subsequent Entry Biologic Market Size (2016-2027) 6.2 North America Bio Similars/Subsequent Entry Biologic Market Size by Type 6.2.1 North America Bio Similars/Subsequent Entry Biologic Market Size by Type (2016-2021) 6.2.2 North America Bio Similars/Subsequent Entry Biologic Market Size by Type (2022-2027) 6.2.3 North America Bio Similars/Subsequent Entry Biologic Market Size by Type (2016-2027) 6.3 North America Bio Similars/Subsequent Entry Biologic Market Size by Application 6.3.1 North America Bio Similars/Subsequent Entry Biologic Market Size by Application (2016-2021) 6.3.2 North America Bio Similars/Subsequent Entry Biologic Market Size by Application (2022-2027) 6.3.3 North America Bio Similars/Subsequent Entry Biologic Market Size by Application (2016-2027) 6.4 North America Bio Similars/Subsequent Entry Biologic Market Size by Country 6.4.1 North America Bio Similars/Subsequent Entry Biologic Market Size by Country (2016-2021) 6.4.2 North America Bio Similars/Subsequent Entry Biologic Market Size by Country (2022-2027) 6.4.3 United States 6.4.3 Canada 7 Europe 7.1 Europe Bio Similars/Subsequent Entry Biologic Market Size (2016-2027) 7.2 Europe Bio Similars/Subsequent Entry Biologic Market Size by Type 7.2.1 Europe Bio Similars/Subsequent Entry Biologic Market Size by Type (2016-2021) 7.2.2 Europe Bio Similars/Subsequent Entry Biologic Market Size by Type (2022-2027) 7.2.3 Europe Bio Similars/Subsequent Entry Biologic Market Size by Type (2016-2027) 7.3 Europe Bio Similars/Subsequent Entry Biologic Market Size by Application 7.3.1 Europe Bio Similars/Subsequent Entry Biologic Market Size by Application (2016-2021) 7.3.2 Europe Bio Similars/Subsequent Entry Biologic Market Size by Application (2022-2027) 7.3.3 Europe Bio Similars/Subsequent Entry Biologic Market Size by Application (2016-2027) 7.4 Europe Bio Similars/Subsequent Entry Biologic Market Size by Country 7.4.1 Europe Bio Similars/Subsequent Entry Biologic Market Size by Country (2016-2021) 7.4.2 Europe Bio Similars/Subsequent Entry Biologic Market Size by Country (2022-2027) 7.4.3 Germany 7.4.4 France 7.4.5 U.K. 7.4.6 Italy 7.4.7 Russia 7.4.8 Nordic 8 Asia-Pacific 8.1 Asia-Pacific Bio Similars/Subsequent Entry Biologic Market Size (2016-2027) 8.2 Asia-Pacific Bio Similars/Subsequent Entry Biologic Market Size by Type 8.2.1 Asia-Pacific Bio Similars/Subsequent Entry Biologic Market Size by Type (2016-2021) 8.2.2 Asia-Pacific Bio Similars/Subsequent Entry Biologic Market Size by Type (2022-2027) 8.2.3 Asia-Pacific Bio Similars/Subsequent Entry Biologic Market Size by Type (2016-2027) 8.3 Asia-Pacific Bio Similars/Subsequent Entry Biologic Market Size by Application 8.3.1 Asia-Pacific Bio Similars/Subsequent Entry Biologic Market Size by Application (2016-2021) 8.3.2 Asia-Pacific Bio Similars/Subsequent Entry Biologic Market Size by Application (2022-2027) 8.3.3 Asia-Pacific Bio Similars/Subsequent Entry Biologic Market Size by Application (2016-2027) 8.4 Asia-Pacific Bio Similars/Subsequent Entry Biologic Market Size by Region 8.4.1 Asia-Pacific Bio Similars/Subsequent Entry Biologic Market Size by Region (2016-2021) 8.4.2 Asia-Pacific Bio Similars/Subsequent Entry Biologic Market Size by Region (2022-2027) 8.4.3 China 8.4.4 Japan 8.4.5 South Korea 8.4.6 Southeast Asia 8.4.7 India 8.4.8 Australia 9 Latin America 9.1 Latin America Bio Similars/Subsequent Entry Biologic Market Size (2016-2027) 9.2 Latin America Bio Similars/Subsequent Entry Biologic Market Size by Type 9.2.1 Latin America Bio Similars/Subsequent Entry Biologic Market Size by Type (2016-2021) 9.2.2 Latin America Bio Similars/Subsequent Entry Biologic Market Size by Type (2022-2027) 9.2.3 Latin America Bio Similars/Subsequent Entry Biologic Market Size by Type (2016-2027) 9.3 Latin America Bio Similars/Subsequent Entry Biologic Market Size by Application 9.3.1 Latin America Bio Similars/Subsequent Entry Biologic Market Size by Application (2016-2021) 9.3.2 Latin America Bio Similars/Subsequent Entry Biologic Market Size by Application (2022-2027) 9.3.3 Latin America Bio Similars/Subsequent Entry Biologic Market Size by Application (2016-2027) 9.4 Latin America Bio Similars/Subsequent Entry Biologic Market Size by Country 9.4.1 Latin America Bio Similars/Subsequent Entry Biologic Market Size by Country (2016-2021) 9.4.2 Latin America Bio Similars/Subsequent Entry Biologic Market Size by Country (2022-2027) 9.4.3 Mexico 9.4.4 Brazil 10 Middle East & Africa 10.1 Middle East & Africa Bio Similars/Subsequent Entry Biologic Market Size (2016-2027) 10.2 Middle East & Africa Bio Similars/Subsequent Entry Biologic Market Size by Type 10.2.1 Middle East & Africa Bio Similars/Subsequent Entry Biologic Market Size by Type (2016-2021) 10.2.2 Middle East & Africa Bio Similars/Subsequent Entry Biologic Market Size by Type (2022-2027) 10.2.3 Middle East & Africa Bio Similars/Subsequent Entry Biologic Market Size by Type (2016-2027) 10.3 Middle East & Africa Bio Similars/Subsequent Entry Biologic Market Size by Application 10.3.1 Middle East & Africa Bio Similars/Subsequent Entry Biologic Market Size by Application (2016-2021) 10.3.2 Middle East & Africa Bio Similars/Subsequent Entry Biologic Market Size by Application (2022-2027) 10.3.3 Middle East & Africa Bio Similars/Subsequent Entry Biologic Market Size by Application (2016-2027) 10.4 Middle East & Africa Bio Similars/Subsequent Entry Biologic Market Size by Country 10.4.1 Middle East & Africa Bio Similars/Subsequent Entry Biologic Market Size by Country (2016-2021) 10.4.2 Middle East & Africa Bio Similars/Subsequent Entry Biologic Market Size by Country (2022-2027) 10.4.3 Turkey 10.4.4 Saudi Arabia 10.4.5 UAE 11 Key Players Profiles 11.1 Sun Pharma 11.1.1 Sun Pharma Company Details 11.1.2 Sun Pharma Business Overview 11.1.3 Sun Pharma Bio Similars/Subsequent Entry Biologic Introduction 11.1.4 Sun Pharma Revenue in Bio Similars/Subsequent Entry Biologic Business (2016-2021) 11.1.5 Sun Pharma Recent Development 11.2 Synthon Pharmaceuticals 11.2.1 Synthon Pharmaceuticals Company Details 11.2.2 Synthon Pharmaceuticals Business Overview 11.2.3 Synthon Pharmaceuticals Bio Similars/Subsequent Entry Biologic Introduction 11.2.4 Synthon Pharmaceuticals Revenue in Bio Similars/Subsequent Entry Biologic Business (2016-2021) 11.2.5 Synthon Pharmaceuticals Recent Development 11.3 Teva Pharmaceutical Industries 11.3.1 Teva Pharmaceutical Industries Company Details 11.3.2 Teva Pharmaceutical Industries Business Overview 11.3.3 Teva Pharmaceutical Industries Bio Similars/Subsequent Entry Biologic Introduction 11.3.4 Teva Pharmaceutical Industries Revenue in Bio Similars/Subsequent Entry Biologic Business (2016-2021) 11.3.5 Teva Pharmaceutical Industries Recent Development 11.4 LG Life Sciences 11.4.1 LG Life Sciences Company Details 11.4.2 LG Life Sciences Business Overview 11.4.3 LG Life Sciences Bio Similars/Subsequent Entry Biologic Introduction 11.4.4 LG Life Sciences Revenue in Bio Similars/Subsequent Entry Biologic Business (2016-2021) 11.4.5 LG Life Sciences Recent Development 11.5 Celltrion Biocon 11.5.1 Celltrion Biocon Company Details 11.5.2 Celltrion Biocon Business Overview 11.5.3 Celltrion Biocon Bio Similars/Subsequent Entry Biologic Introduction 11.5.4 Celltrion Biocon Revenue in Bio Similars/Subsequent Entry Biologic Business (2016-2021) 11.5.5 Celltrion Biocon Recent Development 11.6 Hospira 11.6.1 Hospira Company Details 11.6.2 Hospira Business Overview 11.6.3 Hospira Bio Similars/Subsequent Entry Biologic Introduction 11.6.4 Hospira Revenue in Bio Similars/Subsequent Entry Biologic Business (2016-2021) 11.6.5 Hospira Recent Development 11.7 Merck 11.7.1 Merck Company Details 11.7.2 Merck Business Overview 11.7.3 Merck Bio Similars/Subsequent Entry Biologic Introduction 11.7.4 Merck Revenue in Bio Similars/Subsequent Entry Biologic Business (2016-2021) 11.7.5 Merck Recent Development 11.8 Biogen idec 11.8.1 Biogen idec Company Details 11.8.2 Biogen idec Business Overview 11.8.3 Biogen idec Bio Similars/Subsequent Entry Biologic Introduction 11.8.4 Biogen idec Revenue in Bio Similars/Subsequent Entry Biologic Business (2016-2021) 11.8.5 Biogen idec Recent Development 11.9 Genentech (Roche) 11.9.1 Genentech (Roche) Company Details 11.9.2 Genentech (Roche) Business Overview 11.9.3 Genentech (Roche) Bio Similars/Subsequent Entry Biologic Introduction 11.9.4 Genentech (Roche) Revenue in Bio Similars/Subsequent Entry Biologic Business (2016-2021) 11.9.5 Genentech (Roche) Recent Development 11.10 Pfizer 11.10.1 Pfizer Company Details 11.10.2 Pfizer Business Overview 11.10.3 Pfizer Bio Similars/Subsequent Entry Biologic Introduction 11.10.4 Pfizer Revenue in Bio Similars/Subsequent Entry Biologic Business (2016-2021) 11.10.5 Pfizer Recent Development 11.11 Celltrion 11.11.1 Celltrion Company Details 11.11.2 Celltrion Business Overview 11.11.3 Celltrion Bio Similars/Subsequent Entry Biologic Introduction 11.11.4 Celltrion Revenue in Bio Similars/Subsequent Entry Biologic Business (2016-2021) 11.11.5 Celltrion Recent Development 11.12 Biocon 11.12.1 Biocon Company Details 11.12.2 Biocon Business Overview 11.12.3 Biocon Bio Similars/Subsequent Entry Biologic Introduction 11.12.4 Biocon Revenue in Bio Similars/Subsequent Entry Biologic Business (2016-2021) 11.12.5 Biocon Recent Development 11.13 Amgen 11.13.1 Amgen Company Details 11.13.2 Amgen Business Overview 11.13.3 Amgen Bio Similars/Subsequent Entry Biologic Introduction 11.13.4 Amgen Revenue in Bio Similars/Subsequent Entry Biologic Business (2016-2021) 11.13.5 Amgen Recent Development 11.14 Samsung Biologics 11.14.1 Samsung Biologics Company Details 11.14.2 Samsung Biologics Business Overview 11.14.3 Samsung Biologics Bio Similars/Subsequent Entry Biologic Introduction 11.14.4 Samsung Biologics Revenue in Bio Similars/Subsequent Entry Biologic Business (2016-2021) 11.14.5 Samsung Biologics Recent Development 11.15 Mylan 11.15.1 Mylan Company Details 11.15.2 Mylan Business Overview 11.15.3 Mylan Bio Similars/Subsequent Entry Biologic Introduction 11.15.4 Mylan Revenue in Bio Similars/Subsequent Entry Biologic Business (2016-2021) 11.15.5 Mylan Recent Development 11.16 Dr. Reddy's Laboratories 11.16.1 Dr. Reddy's Laboratories Company Details 11.16.2 Dr. Reddy's Laboratories Business Overview 11.16.3 Dr. Reddy's Laboratories Bio Similars/Subsequent Entry Biologic Introduction 11.16.4 Dr. Reddy's Laboratories Revenue in Bio Similars/Subsequent Entry Biologic Business (2016-2021) 11.16.5 Dr. Reddy's Laboratories Recent Development 11.17 Stada Arzneimittel AG 11.17.1 Stada Arzneimittel AG Company Details 11.17.2 Stada Arzneimittel AG Business Overview 11.17.3 Stada Arzneimittel AG Bio Similars/Subsequent Entry Biologic Introduction 11.17.4 Stada Arzneimittel AG Revenue in Bio Similars/Subsequent Entry Biologic Business (2016-2021) 11.17.5 Stada Arzneimittel AG Recent Development 11.18 AbbVie 11.18.1 AbbVie Company Details 11.18.2 AbbVie Business Overview 11.18.3 AbbVie Bio Similars/Subsequent Entry Biologic Introduction 11.18.4 AbbVie Revenue in Bio Similars/Subsequent Entry Biologic Business (2016-2021) 11.18.5 AbbVie Recent Development 11.18 Sanofi-Aventis 11.25.1 Sanofi-Aventis Company Details 11.25.2 Sanofi-Aventis Business Overview 11.25.3 Sanofi-Aventis Bio Similars/Subsequent Entry Biologic Introduction 11.25.4 Sanofi-Aventis Revenue in Bio Similars/Subsequent Entry Biologic Business (2016-2021) 11.25.5 Sanofi-Aventis Recent Development 11.20 Johnson & Johnson 11.20.1 Johnson & Johnson Company Details 11.20.2 Johnson & Johnson Business Overview 11.20.3 Johnson & Johnson Bio Similars/Subsequent Entry Biologic Introduction 11.20.4 Johnson & Johnson Revenue in Bio Similars/Subsequent Entry Biologic Business (2016-2021) 11.20.5 Johnson & Johnson Recent Development 11.21 Novo Nordisk 11.21.1 Novo Nordisk Company Details 11.21.2 Novo Nordisk Business Overview 11.21.3 Novo Nordisk Bio Similars/Subsequent Entry Biologic Introduction 11.21.4 Novo Nordisk Revenue in Bio Similars/Subsequent Entry Biologic Business (2016-2021) 11.21.5 Novo Nordisk Recent Development 11.22 Eli Lilly 11.22.1 Eli Lilly Company Details 11.22.2 Eli Lilly Business Overview 11.22.3 Eli Lilly Bio Similars/Subsequent Entry Biologic Introduction 11.22.4 Eli Lilly Revenue in Bio Similars/Subsequent Entry Biologic Business (2016-2021) 11.22.5 Eli Lilly Recent Development 11.23 Novartis 11.23.1 Novartis Company Details 11.23.2 Novartis Business Overview 11.23.3 Novartis Bio Similars/Subsequent Entry Biologic Introduction 11.23.4 Novartis Revenue in Bio Similars/Subsequent Entry Biologic Business (2016-2021) 11.23.5 Novartis Recent Development 11.24 3sbio 11.24.1 3sbio Company Details 11.24.2 3sbio Business Overview 11.24.3 3sbio Bio Similars/Subsequent Entry Biologic Introduction 11.24.4 3sbio Revenue in Bio Similars/Subsequent Entry Biologic Business (2016-2021) 11.24.5 3sbio Recent Development 11.25 Biotech 11.25.1 Biotech Company Details 11.25.2 Biotech Business Overview 11.25.3 Biotech Bio Similars/Subsequent Entry Biologic Introduction 11.25.4 Biotech Revenue in Bio Similars/Subsequent Entry Biologic Business (2016-2021) 11.25.5 Biotech Recent Development 11.26 Gelgen 11.26.1 Gelgen Company Details 11.26.2 Gelgen Business Overview 11.26.3 Gelgen Bio Similars/Subsequent Entry Biologic Introduction 11.26.4 Gelgen Revenue in Bio Similars/Subsequent Entry Biologic Business (2016-2021) 11.26.5 Gelgen Recent Development 11.27 Innovent 11.27.1 Innovent Company Details 11.27.2 Innovent Business Overview 11.27.3 Innovent Bio Similars/Subsequent Entry Biologic Introduction 11.27.4 Innovent Revenue in Bio Similars/Subsequent Entry Biologic Business (2016-2021) 11.27.5 Innovent Recent Development 11.28 Dong Bao 11.28.1 Dong Bao Company Details 11.28.2 Dong Bao Business Overview 11.28.3 Dong Bao Bio Similars/Subsequent Entry Biologic Introduction 11.28.4 Dong Bao Revenue in Bio Similars/Subsequent Entry Biologic Business (2016-2021) 11.28.5 Dong Bao Recent Development 11.29 Ganlee 11.29.1 Ganlee Company Details 11.29.2 Ganlee Business Overview 11.29.3 Ganlee Bio Similars/Subsequent Entry Biologic Introduction 11.29.4 Ganlee Revenue in Bio Similars/Subsequent Entry Biologic Business (2016-2021) 11.29.5 Ganlee Recent Development 12 Analyst's Viewpoints/Conclusions 13 Appendix 13.1 Research Methodology 13.1.1 Methodology/Research Approach 13.1.2 Data Source 13.2 Disclaimer 13.3 Author Details

List of Tables Table 1. Global Bio Similars/Subsequent Entry Biologic Market Size Growth Rate by Type (US$ Million):2016 VS 2021 VS 2027 Table 2. Key Players of Monoclonal Antibodies Table 3. Key Players of Interferon Table 4. Key Players of Erythropoietin Table 5. Key Players of Insulin Table 6. Key Players of Vaccines Table 7. Key Players of Other Table 8. Global Bio Similars/Subsequent Entry Biologic Market Size Growth by Application (US$ Million): 2016 VS 2021 VS 2027 Table 9. Global Bio Similars/Subsequent Entry Biologic Market Size by Regions (US$ Million): 2016 VS 2021 VS 2027 Table 10. Global Bio Similars/Subsequent Entry Biologic Market Size by Regions (2016-2021) & (US$ Million) Table 11. Global Bio Similars/Subsequent Entry Biologic Market Share by Regions (2016-2021) Table 12. Global Bio Similars/Subsequent Entry Biologic Forecasted Market Size by Regions (2022-2027) & (US$ Million) Table 13. Global Bio Similars/Subsequent Entry Biologic Market Share by Regions (2022-2027) Table 14. Bio Similars/Subsequent Entry Biologic Market Trends Table 15. Bio Similars/Subsequent Entry Biologic Market Drivers Table 16. Bio Similars/Subsequent Entry Biologic Market Challenges Table 17. Bio Similars/Subsequent Entry Biologic Market Restraints Table 18. Global Bio Similars/Subsequent Entry Biologic Revenue by Players (2016-2021) & (US$ Million) Table 19. Global Bio Similars/Subsequent Entry Biologic Market Share by Players (2016-2021) Table 20. Global Top Bio Similars/Subsequent Entry Biologic Players by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Bio Similars/Subsequent Entry Biologic as of 2020) Table 21. Ranking of Global Top Bio Similars/Subsequent Entry Biologic Companies by Revenue (US$ Million) in 2020 Table 22. Global 5 Largest Players Market Share by Bio Similars/Subsequent Entry Biologic Revenue (CR5 and HHI) & (2016-2021) Table 23. Key Players Headquarters and Area Served Table 24. Key Players Bio Similars/Subsequent Entry Biologic Product Solution and Service Table 25. Date of Enter into Bio Similars/Subsequent Entry Biologic Market Table 26. Mergers & Acquisitions, Expansion Plans Table 27. Global Bio Similars/Subsequent Entry Biologic Market Size by Type (2016-2021) (US$ Million) Table 28. Global Bio Similars/Subsequent Entry Biologic Revenue Market Share by Type (2016-2021) Table 29. Global Bio Similars/Subsequent Entry Biologic Forecasted Market Size by Type (2022-2027) (US$ Million) Table 30. Global Bio Similars/Subsequent Entry Biologic Revenue Market Share by Type (2022-2027) & (US$ Million) Table 31. Global Bio Similars/Subsequent Entry Biologic Market Size Share by Application (2016-2021) & (US$ Million) Table 32. Global Bio Similars/Subsequent Entry Biologic Revenue Market Share by Application (2016-2021) Table 33. Global Bio Similars/Subsequent Entry Biologic Forecasted Market Size by Application (2022-2027) (US$ Million) Table 34. Global Bio Similars/Subsequent Entry Biologic Revenue Market Share by Application (2022-2027) & (US$ Million) Table 35. North America Bio Similars/Subsequent Entry Biologic Market Size by Type (2016-2021) (US$ Million) Table 36. North America Bio Similars/Subsequent Entry Biologic Market Size by Type (2022-2027) & (US$ Million) Table 37. North America Bio Similars/Subsequent Entry Biologic Market Size by Application (2016-2021) (US$ Million) Table 38. North America Bio Similars/Subsequent Entry Biologic Market Size by Application (2022-2027) & (US$ Million) Table 39. North America Bio Similars/Subsequent Entry Biologic Market Size by Country (2016-2021) & (US$ Million) Table 40. North America Bio Similars/Subsequent Entry Biologic Market Size by Country (2022-2027) & (US$ Million) Table 41. Europe Bio Similars/Subsequent Entry Biologic Market Size by Type (2016-2021) (US$ Million) Table 42. Europe Bio Similars/Subsequent Entry Biologic Market Size by Type (2022-2027) & (US$ Million) Table 43. Europe Bio Similars/Subsequent Entry Biologic Market Size by Application (2016-2021) (US$ Million) Table 44. Europe Bio Similars/Subsequent Entry Biologic Market Size by Application (2022-2027) & (US$ Million) Table 45. Europe Bio Similars/Subsequent Entry Biologic Market Size by Country (2016-2021) & (US$ Million) Table 46. Europe Bio Similars/Subsequent Entry Biologic Market Size by Country (2022-2027) & (US$ Million) Table 47. Asia-Pacific Bio Similars/Subsequent Entry Biologic Market Size by Type (2016-2021) (US$ Million) Table 48. Asia-Pacific Bio Similars/Subsequent Entry Biologic Market Size by Type (2022-2027) & (US$ Million) Table 49. Asia-Pacific Bio Similars/Subsequent Entry Biologic Market Size by Application (2016-2021) (US$ Million) Table 50. Asia-Pacific Bio Similars/Subsequent Entry Biologic Market Size by Application (2022-2027) & (US$ Million) Table 51. Asia-Pacific Bio Similars/Subsequent Entry Biologic Market Size by Region (2016-2021) & (US$ Million) Table 52. Asia-Pacific Bio Similars/Subsequent Entry Biologic Market Size by Region (2022-2027) & (US$ Million) Table 53. Latin America Bio Similars/Subsequent Entry Biologic Market Size by Type (2016-2021) (US$ Million) Table 54. Latin America Bio Similars/Subsequent Entry Biologic Market Size by Type (2022-2027) & (US$ Million) Table 55. Latin America Bio Similars/Subsequent Entry Biologic Market Size by Application (2016-2021) (US$ Million) Table 56. Latin America Bio Similars/Subsequent Entry Biologic Market Size by Application (2022-2027) & (US$ Million) Table 57. Latin America Bio Similars/Subsequent Entry Biologic Market Size by Country (2016-2021) & (US$ Million) Table 58. Latin America Bio Similars/Subsequent Entry Biologic Market Size by Country (2022-2027) & (US$ Million) Table 59. Middle East & Africa Bio Similars/Subsequent Entry Biologic Market Size by Type (2016-2021) (US$ Million) Table 60. Middle East & Africa Bio Similars/Subsequent Entry Biologic Market Size by Type (2022-2027) & (US$ Million) Table 61. Middle East & Africa Bio Similars/Subsequent Entry Biologic Market Size by Application (2016-2021) (US$ Million) Table 62. Middle East & Africa Bio Similars/Subsequent Entry Biologic Market Size by Application (2022-2027) & (US$ Million) Table 63. Middle East & Africa Bio Similars/Subsequent Entry Biologic Market Size by Country (2016-2021) & (US$ Million) Table 64. Middle East & Africa Bio Similars/Subsequent Entry Biologic Market Size by Country (2022-2027) & (US$ Million) Table 65. Sun Pharma Company Details Table 66. Sun Pharma Business Overview Table 67. Sun Pharma Bio Similars/Subsequent Entry Biologic Product Table 68. Sun Pharma Revenue in Bio Similars/Subsequent Entry Biologic Business (2016-2021) & (US$ Million) Table 69. Sun Pharma Recent Development Table 70. Synthon Pharmaceuticals Company Details Table 71. Synthon Pharmaceuticals Business Overview Table 72. Synthon Pharmaceuticals Bio Similars/Subsequent Entry Biologic Product Table 73. Synthon Pharmaceuticals Revenue in Bio Similars/Subsequent Entry Biologic Business (2016-2021) & (US$ Million) Table 74. Synthon Pharmaceuticals Recent Development Table 75. Teva Pharmaceutical Industries Company Details Table 76. Teva Pharmaceutical Industries Business Overview Table 77. Teva Pharmaceutical Industries Bio Similars/Subsequent Entry Biologic Product Table 78. Teva Pharmaceutical Industries Revenue in Bio Similars/Subsequent Entry Biologic Business (2016-2021) & (US$ Million) Table 79. Teva Pharmaceutical Industries Recent Development Table 80. LG Life Sciences Company Details Table 81. LG Life Sciences Business Overview Table 82. LG Life Sciences Bio Similars/Subsequent Entry Biologic Product Table 83. LG Life Sciences Revenue in Bio Similars/Subsequent Entry Biologic Business (2016-2021) & (US$ Million) Table 84. LG Life Sciences Recent Development Table 85. Celltrion Biocon Company Details Table 86. Celltrion Biocon Business Overview Table 87. Celltrion Biocon Bio Similars/Subsequent Entry Biologic Product Table 88. Celltrion Biocon Revenue in Bio Similars/Subsequent Entry Biologic Business (2016-2021) & (US$ Million) Table 89. Celltrion Biocon Recent Development Table 90. Hospira Company Details Table 91. Hospira Business Overview Table 92. Hospira Bio Similars/Subsequent Entry Biologic Product Table 93. Hospira Revenue in Bio Similars/Subsequent Entry Biologic Business (2016-2021) & (US$ Million) Table 94. Hospira Recent Development Table 95. Merck Company Details Table 96. Merck Business Overview Table 97. Merck Bio Similars/Subsequent Entry Biologic Product Table 98. Merck Revenue in Bio Similars/Subsequent Entry Biologic Business (2016-2021) & (US$ Million) Table 99. Merck Recent Development Table 100. Biogen idec Company Details Table 101. Biogen idec Business Overview Table 102. Biogen idec Revenue in Bio Similars/Subsequent Entry Biologic Business (2016-2021) & (US$ Million) Table 103. Biogen idec Recent Development Table 104. Genentech (Roche) Company Details Table 105. Genentech (Roche) Business Overview Table 106. Genentech (Roche) Bio Similars/Subsequent Entry Biologic Product Table 107. Genentech (Roche) Revenue in Bio Similars/Subsequent Entry Biologic Business (2016-2021) & (US$ Million) Table 108. Genentech (Roche) Recent Development Table 109. Pfizer Company Details Table 110. Pfizer Business Overview Table 111. Pfizer Bio Similars/Subsequent Entry Biologic Product Table 112. Pfizer Revenue in Bio Similars/Subsequent Entry Biologic Business (2016-2021) & (US$ Million) Table 113. Pfizer Recent Development Table 114. Celltrion Company Details Table 115. Celltrion Business Overview Table 116. Celltrion Bio Similars/Subsequent Entry Biologic Product Table 117. Celltrion Revenue in Bio Similars/Subsequent Entry Biologic Business (2016-2021) & (US$ Million) Table 118. Celltrion Recent Development Table 119. Biocon Company Details Table 120. Biocon Business Overview Table 121. Biocon Bio Similars/Subsequent Entry Biologic Product Table 122. Biocon Revenue in Bio Similars/Subsequent Entry Biologic Business (2016-2021) & (US$ Million) Table 123. Biocon Recent Development Table 124. Amgen Company Details Table 125. Amgen Business Overview Table 126. Amgen Bio Similars/Subsequent Entry Biologic Product Table 127. Amgen Revenue in Bio Similars/Subsequent Entry Biologic Business (2016-2021) & (US$ Million) Table 128. Amgen Recent Development Table 129. Samsung Biologics Company Details Table 130. Samsung Biologics Business Overview Table 131. Samsung Biologics Bio Similars/Subsequent Entry Biologic Product Table 132. Samsung Biologics Revenue in Bio Similars/Subsequent Entry Biologic Business (2016-2021) & (US$ Million) Table 133. Samsung Biologics Recent Development Table 134. Mylan Company Details Table 135. Mylan Business Overview Table 136. Mylan Bio Similars/Subsequent Entry Biologic Product Table 137. Mylan Revenue in Bio Similars/Subsequent Entry Biologic Business (2016-2021) & (US$ Million) Table 138. Mylan Recent Development Table 139. Dr. Reddy's Laboratories Company Details Table 140. Dr. Reddy's Laboratories Business Overview Table 141. Dr. Reddy's Laboratories Bio Similars/Subsequent Entry Biologic Product Table 142. Dr. Reddy's Laboratories Revenue in Bio Similars/Subsequent Entry Biologic Business (2016-2021) & (US$ Million) Table 143. Dr. Reddy's Laboratories Recent Development Table 144. Stada Arzneimittel AG Company Details Table 145. Stada Arzneimittel AG Business Overview Table 146. Stada Arzneimittel AG Bio Similars/Subsequent Entry Biologic Product Table 147. Stada Arzneimittel AG Revenue in Bio Similars/Subsequent Entry Biologic Business (2016-2021) & (US$ Million) Table 148. Stada Arzneimittel AG Recent Development Table 149. AbbVie Company Details Table 150. AbbVie Business Overview Table 151. AbbVie Bio Similars/Subsequent Entry Biologic Product Table 152. AbbVie Revenue in Bio Similars/Subsequent Entry Biologic Business (2016-2021) & (US$ Million) Table 153. AbbVie Recent Development Table 154. Sanofi-Aventis Company Details Table 155. Sanofi-Aventis Business Overview Table 156. Sanofi-Aventis Bio Similars/Subsequent Entry Biologic Product Table 157. Sanofi-Aventis Revenue in Bio Similars/Subsequent Entry Biologic Business (2016-2021) & (US$ Million) Table 158. Sanofi-Aventis Recent Development Table 159. Johnson & Johnson Company Details Table 160. Johnson & Johnson Business Overview Table 161. Johnson & Johnson Bio Similars/Subsequent Entry Biologic Product Table 162. Johnson & Johnson Revenue in Bio Similars/Subsequent Entry Biologic Business (2016-2021) & (US$ Million) Table 163. Johnson & Johnson Recent Development Table 164. Novo Nordisk Company Details Table 165. Novo Nordisk Business Overview Table 166. Novo Nordisk Bio Similars/Subsequent Entry Biologic Product Table 167. Novo Nordisk Revenue in Bio Similars/Subsequent Entry Biologic Business (2016-2021) & (US$ Million) Table 168. Novo Nordisk Recent Development Table 169. Eli Lilly Company Details Table 170. Eli Lilly Business Overview Table 171. Eli Lilly Bio Similars/Subsequent Entry Biologic Product Table 172. Eli Lilly Revenue in Bio Similars/Subsequent Entry Biologic Business (2016-2021) & (US$ Million) Table 173. Eli Lilly Recent Development Table 174. Novartis Company Details Table 175. Novartis Business Overview Table 176. Novartis Bio Similars/Subsequent Entry Biologic Product Table 177. Novartis Revenue in Bio Similars/Subsequent Entry Biologic Business (2016-2021) & (US$ Million) Table 178. Novartis Recent Development Table 179. 3sbio Company Details Table 180. 3sbio Business Overview Table 181. 3sbio Bio Similars/Subsequent Entry BiologicProduct Table 182. 3sbio Revenue in Bio Similars/Subsequent Entry Biologic Business (2016-2021) & (US$ Million) Table 183. 3sbio Recent Development Table 184. Biotech Company Details Table 185. Biotech Business Overview Table 186. Biotech Bio Similars/Subsequent Entry Biologic Product Table 187. Biotech Revenue in Bio Similars/Subsequent Entry Biologic Business (2016-2021) & (US$ Million) Table 188. Biotech Recent Development Table 189. Gelgen Company Details Table 190. Gelgen Business Overview Table 191. Gelgen Bio Similars/Subsequent Entry Biologic Product Table 192. Gelgen Revenue in Bio Similars/Subsequent Entry Biologic Business (2016-2021) & (US$ Million) Table 193. Gelgen Recent Development Table 194. Innovent Company Details Table 195. Innovent Business Overview Table 196. Innovent Bio Similars/Subsequent Entry Biologic Product Table 197. Innovent Revenue in Bio Similars/Subsequent Entry Biologic Business (2016-2021) & (US$ Million) Table 198. Innovent Recent Development Table 199. Dong Bao Company Details Table 200. Dong Bao Business Overview Table 201. Dong Bao Bio Similars/Subsequent Entry Biologic Product Table 202. Dong Bao Revenue in Bio Similars/Subsequent Entry Biologic Business (2016-2021) & (US$ Million) Table 203. Dong Bao Recent Development Table 204. Ganlee Company Details Table 205. Ganlee Business Overview Table 206. Ganlee Bio Similars/Subsequent Entry Biologic Product Table 207. Ganlee Revenue in Bio Similars/Subsequent Entry Biologic Business (2016-2021) & (US$ Million) Table 208. Ganlee Recent Development Table 209. Research Programs/Design for This Report Table 210. Key Data Information from Secondary Sources Table 211. Key Data Information from Primary Sources List of Figures Figure 1. Global Bio Similars/Subsequent Entry Biologic Market Share by Type: 2020 VS 2027 Figure 2. Monoclonal Antibodies Features Figure 3. Interferon Features Figure 4. Erythropoietin Features Figure 5. Insulin Features Figure 6. Vaccines Features Figure 7. Other Features Figure 8. Global Bio Similars/Subsequent Entry Biologic Market Share by Application: 2020 VS 2027 Figure 9. Tumor Case Studies Figure 10. Diabetes Case Studies Figure 11. Cardiovascular Case Studies Figure 12. Hemophilia Case Studies Figure 13. Other Case Studies Figure 14. Bio Similars/Subsequent Entry Biologic Report Years Considered Figure 15. Global Bio Similars/Subsequent Entry Biologic Market Size (US$ Million), Year-over-Year: 2016-2027 Figure 16. Global Bio Similars/Subsequent Entry Biologic Market Size (US$ Million), 2016 VS 2021 VS 2027 Figure 17. Global Bio Similars/Subsequent Entry Biologic Market Share by Regions: 2020 VS 2027 Figure 18. Global Bio Similars/Subsequent Entry Biologic Market Share by Regions (2022-2027) Figure 19. Global Bio Similars/Subsequent Entry Biologic Market Share by Players in 2020 Figure 20. Global Top Bio Similars/Subsequent Entry Biologic Players by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Bio Similars/Subsequent Entry Biologic as of 2020 Figure 21. The Top 10 and 5 Players Market Share by Bio Similars/Subsequent Entry Biologic Revenue in 2020 Figure 22. Global Bio Similars/Subsequent Entry Biologic Revenue Market Share by Type (2016-2021) Figure 23. Global Bio Similars/Subsequent Entry Biologic Revenue Market Share by Type (2022-2027) Figure 24. North America Bio Similars/Subsequent Entry Biologic Market Size YoY Growth (2016-2027) & (US$ Million) Figure 25. North America Bio Similars/Subsequent Entry Biologic Market Share by Type (2016-2027) Figure 26. North America Bio Similars/Subsequent Entry Biologic Market Share by Application (2016-2027) Figure 27. North America Bio Similars/Subsequent Entry Biologic Market Share by Country (2016-2027) Figure 28. United States Bio Similars/Subsequent Entry Biologic Market Size YoY Growth (2016-2027) & (US$ Million) Figure 29. Canada Bio Similars/Subsequent Entry Biologic Market Size YoY Growth (2016-2027) & (US$ Million) Figure 30. Europe Bio Similars/Subsequent Entry Biologic Market Size YoY Growth (2016-2027) & (US$ Million) Figure 31. Europe Bio Similars/Subsequent Entry Biologic Market Share by Type (2016-2027) Figure 32. Europe Bio Similars/Subsequent Entry Biologic Market Share by Application (2016-2027) Figure 33. Europe Bio Similars/Subsequent Entry Biologic Market Share by Country (2016-2027) Figure 34. Germany Bio Similars/Subsequent Entry Biologic Market Size YoY Growth (2016-2027) & (US$ Million) Figure 35. France Bio Similars/Subsequent Entry Biologic Market Size YoY Growth (2016-2027) & (US$ Million) Figure 36. U.K. Bio Similars/Subsequent Entry Biologic Market Size YoY Growth (2016-2027) & (US$ Million) Figure 37. Italy Bio Similars/Subsequent Entry Biologic Market Size YoY Growth (2016-2027) & (US$ Million) Figure 38. Russia Bio Similars/Subsequent Entry Biologic Market Size YoY Growth (2016-2027) & (US$ Million) Figure 39. Nordic Bio Similars/Subsequent Entry Biologic Market Size YoY Growth (2016-2027) & (US$ Million) Figure 40. Asia-Pacific Bio Similars/Subsequent Entry Biologic Market Size YoY Growth (2016-2027) & (US$ Million) Figure 41. Asia-Pacific Bio Similars/Subsequent Entry Biologic Market Share by Type (2016-2027) Figure 42. Asia-Pacific Bio Similars/Subsequent Entry Biologic Market Share by Application (2016-2027) Figure 43. Asia-Pacific Bio Similars/Subsequent Entry Biologic Market Share by Region (2016-2027) Figure 44. China Bio Similars/Subsequent Entry Biologic Market Size YoY Growth (2016-2027) & (US$ Million) Figure 45. Japan Bio Similars/Subsequent Entry Biologic Market Size YoY Growth (2016-2027) & (US$ Million) Figure 46. South Korea Bio Similars/Subsequent Entry Biologic Market Size YoY Growth (2016-2027) & (US$ Million) Figure 47. Southeast Asia Bio Similars/Subsequent Entry Biologic Market Size YoY Growth (2016-2027) & (US$ Million) Figure 48. India Bio Similars/Subsequent Entry Biologic Market Size YoY Growth (2016-2027) & (US$ Million) Figure 49. Australia Bio Similars/Subsequent Entry Biologic Market Size YoY Growth (2016-2027) & (US$ Million) Figure 50. Latin America Bio Similars/Subsequent Entry Biologic Market Size YoY Growth (2016-2027) & (US$ Million) Figure 51. Latin America Bio Similars/Subsequent Entry Biologic Market Share by Type (2016-2027) Figure 52. Latin America Bio Similars/Subsequent Entry Biologic Market Share by Application (2016-2027) Figure 53. Latin America Bio Similars/Subsequent Entry Biologic Market Share by Country (2016-2027) Figure 54. Mexico Bio Similars/Subsequent Entry Biologic Market Size YoY Growth (2016-2027) & (US$ Million) Figure 55. Brazil Bio Similars/Subsequent Entry Biologic Market Size YoY Growth (2016-2027) & (US$ Million) Figure 56. Middle East & Africa Bio Similars/Subsequent Entry Biologic Market Size YoY Growth (2016-2027) & (US$ Million) Figure 57. Middle East & Africa Bio Similars/Subsequent Entry Biologic Market Share by Type (2016-2027) Figure 58. Middle East & Africa Bio Similars/Subsequent Entry Biologic Market Share by Application (2016-2027) Figure 59. Middle East & Africa Bio Similars/Subsequent Entry Biologic Market Share by Country (2016-2027) Figure 60. Turkey Bio Similars/Subsequent Entry Biologic Market Size YoY Growth (2016-2027) & (US$ Million) Figure 61. Saudi Arabia Bio Similars/Subsequent Entry Biologic Market Size YoY Growth (2016-2027) & (US$ Million) Figure 62. UAE Bio Similars/Subsequent Entry Biologic Market Size YoY Growth (2016-2027) & (US$ Million) Figure 63. Sun Pharma Revenue Growth Rate in Bio Similars/Subsequent Entry Biologic Business (2016-2021) Figure 64. Synthon Pharmaceuticals Revenue Growth Rate in Bio Similars/Subsequent Entry Biologic Business (2016-2021) Figure 65. Teva Pharmaceutical Industries Revenue Growth Rate in Bio Similars/Subsequent Entry Biologic Business (2016-2021) Figure 66. LG Life Sciences Revenue Growth Rate in Bio Similars/Subsequent Entry Biologic Business (2016-2021) Figure 67. Celltrion Biocon Revenue Growth Rate in Bio Similars/Subsequent Entry Biologic Business (2016-2021) Figure 68. Hospira Revenue Growth Rate in Bio Similars/Subsequent Entry Biologic Business (2016-2021) Figure 69. Merck Revenue Growth Rate in Bio Similars/Subsequent Entry Biologic Business (2016-2021) Figure 70. Biogen idec Revenue Growth Rate in Bio Similars/Subsequent Entry Biologic Business (2016-2021) Figure 71. Genentech (Roche) Revenue Growth Rate in Bio Similars/Subsequent Entry Biologic Business (2016-2021) Figure 72. Pfizer Revenue Growth Rate in Bio Similars/Subsequent Entry Biologic Business (2016-2021) Figure 73. Celltrion Revenue Growth Rate in Bio Similars/Subsequent Entry Biologic Business (2016-2021) Figure 74. Biocon Revenue Growth Rate in Bio Similars/Subsequent Entry Biologic Business (2016-2021) Figure 75. Amgen Revenue Growth Rate in Bio Similars/Subsequent Entry Biologic Business (2016-2021) Figure 76. Samsung Biologics Revenue Growth Rate in Bio Similars/Subsequent Entry Biologic Business (2016-2021) Figure 77. Mylan Revenue Growth Rate in Bio Similars/Subsequent Entry Biologic Business (2016-2021) Figure 78. Dr. Reddy's Laboratories Revenue Growth Rate in Bio Similars/Subsequent Entry Biologic Business (2016-2021) Figure 79. Stada Arzneimittel AG Revenue Growth Rate in Bio Similars/Subsequent Entry Biologic Business (2016-2021) Figure 80. AbbVie Revenue Growth Rate in Bio Similars/Subsequent Entry Biologic Business (2016-2021) Figure 81. Sanofi-Aventis Revenue Growth Rate in Bio Similars/Subsequent Entry Biologic Business (2016-2021) Figure 82. Johnson & Johnson Revenue Growth Rate in Bio Similars/Subsequent Entry Biologic Business (2016-2021) Figure 83. Novo Nordisk Revenue Growth Rate in Bio Similars/Subsequent Entry Biologic Business (2016-2021) Figure 84. Eli Lilly Revenue Growth Rate in Bio Similars/Subsequent Entry Biologic Business (2016-2021) Figure 85. Novartis Revenue Growth Rate in Bio Similars/Subsequent Entry Biologic Business (2016-2021) Figure 86. 3sbio Revenue Growth Rate in Bio Similars/Subsequent Entry Biologic Business (2016-2021) Figure 87. Biotech Revenue Growth Rate in Bio Similars/Subsequent Entry Biologic Business (2016-2021) Figure 88. Gelgen Revenue Growth Rate in Bio Similars/Subsequent Entry Biologic Business (2016-2021) Figure 89. Innovent Revenue Growth Rate in Bio Similars/Subsequent Entry Biologic Business (2016-2021) Figure 90. Dong Bao Revenue Growth Rate in Bio Similars/Subsequent Entry Biologic Business (2016-2021) Figure 91. Ganlee Revenue Growth Rate in Bio Similars/Subsequent Entry Biologic Business (2016-2021) Figure 92. Bottom-up and Top-down Approaches for This Report Figure 93. Data Triangulation Figure 94. Key Executives Interviewed

Sun Pharma Synthon Pharmaceuticals Teva Pharmaceutical Industries LG Life Sciences Celltrion Biocon Hospira Merck Biogen idec Genentech (Roche) Pfizer Celltrion Biocon Amgen Samsung Biologics Mylan Dr. Reddy's Laboratories Stada Arzneimittel AG AbbVie Sanofi-Aventis Johnson & Johnson Novo Nordisk Eli Lilly Novartis 3sbio Biotech Gelgen Innovent Dong Bao Ganlee